Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

Core Viewpoint - Hims & Hers Health, Inc. has launched the Hims & Hers Multi-Cancer Test by Galleri®, a blood test capable of detecting signals for over 50 types of cancer before symptoms appear, aiming to enhance access to proactive cancer care [1][2]. Group 1: Product Launch and Features - The Multi-Cancer Test by Galleri® can detect signals for more than 50 types of cancer, including those without recommended screenings, and is designed to be taken annually [2][3]. - The test leverages GRAIL's innovative technology to improve early detection of cancer signals in blood, predicting the likely origin of the signal in the body [3][4]. Group 2: Market Context and Importance - Over one in three individuals will develop cancer in their lifetime, with many cancers remaining undetected until later stages, which complicates treatment and worsens outcomes [1][2]. - The introduction of the Galleri test aims to address the gap in early cancer detection, particularly for aggressive cancers that are often diagnosed late [1][4]. Group 3: Pricing and Accessibility - Starting today, Hims & Hers customers can access the Multi-Cancer Test by Galleri® at a $250 discount from the list price, making it more affordable [5].